Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that “remembers” cancer, effectively preventing recurrence. KAIST’s research team has developed an AI-based personalized cancer vaccine design technology that makes this possible and optimizes anticancer effects for each individual.

The research team overcame the limitations of existing neoantigen discovery, which relied primarily on predicting T cell reactivity, and developed an AI-based neoantigen prediction technology that integrally considers both T cell and B cell reactivity.